The European Alliance for Responsible R&D and Affordable Medicines transparency of clinical trials and good governance should be included in the EMA (European Medicines Agency) extended mandate

In occasion of the ongoing trilogues on the European Medicines Agency (EMA) extended mandate, Members of the European Alliance for Responsible R&D and Affordable Medicines urge the Council to ensure the new Regulation enhances clinical trial transparency and upholds good governance.    As explained in a letter published today, it is crucial that information on clinical trials is made available in a timely, user-friendly, and complete manner. This is key to avoid unnecessary duplications and to accelerate the development of new therapies and vaccines, especially during a public health emergency.

• The European Alliance for Responsible R&D and  Affordable Medicines transparency of clinical trials and good governance should be included in the EMA (European Medicines Agency) extended mandate. Brussels, Belgium, 9 September 2021 Download article here.

Or see it in https://medicinesalliance.eu/transparency-of-clinical-trials-and-good-governance-should-be-included-in-the-regulation-reinforcing-the-role-of-the-ema/